X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Half-Million COVID Antibody Doses Sold By AstraZeneca To US

Content Team by Content Team
17th January 2022
in News
Half-Million COVID Antibody Doses Sold By AstraZeneca To US

After topping off supplies to Pfizer and GlaxoSmithkline, of the COVID-19 vaccine, US has sought AstraZeneca’s help of its antibody combo. Notably, the government has already bought another 500,000 doses of antibody cocktail Evusheld plus cilgavimab. This is in addition to the 700,000 doses which US has already placed an order for. The drug maker is estimating to complete the delivery in the first quarter of this year itself.

Unlike the antibody drug which is manufactured by Eli Lilly and GalxoSmithKline this therapeutic from AstraZeneca has been authorised for prevention when it comes to the virus. The FDA in December 2021 has authorised Evusheld to be used in patients suffering from moderate to severely compromised immunity either through some medical condition or through suppressive medications.

According to statement released by one of the top management executives of AstraZeneca, the agreement which has taken place on 12th January 2021 will provide protection to the most vulnerable sections of the society especially to the ones who are immunocompromised and as of now do not have many options in a scenario where the numbers are rapidly rising.

When it comes to the commercials, AstraZeneca hasn’t confirmed any number which the Government will be paying for the recently ordered doses. However, the additional details as per the company will emerge in a few weeks.

Evusheld is one of the two antibody therapies which has been authorized for the fight against Omicron and other variants and has shown neutralizing effects. The company has attributed the efficacy of Evusheld to the two potent antibodies that have varied and alike activities against the virus. The antibody cocktail because of this evades the potential resistance as and when the variants crop up.

America has made it a conditioned approach of upping the storage of COVID-19 therapeutics. It has already ordered Paxlovid which is Pfizer’s antiviral pill for 30 million courses. And just a day before the AstraZeneca deal, the government has locked 600,000 doses of GlaxoSmithKline of their antibody sotrovimab which they plan to deliver in the first quarter.

Previous Post

Ensovibep Therepeutic Candidate To Fight COVID-19 Makes Way

Next Post

LJI and Charles River Laboratories to collaborate on COVID-19 research

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post
Takeda

LJI and Charles River Laboratories to collaborate on COVID-19 research

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In